Senior Manager, Data Product Owner, Market Access
$164k/y-$205k/y
Revolution Medicinesa day ago
Highlight
OnsiteFull-timeSenior
Summary
Revolution Medicines is seeking a Senior Manager, Data Product Owner, Market Access to join their team in the San Francisco Bay Area. The role involves managing data products to support commercialization efforts in precision oncology.
About the Role
As a Senior Manager, Data Product Owner, you will report to the Director of Data Solutions and work closely with the Commercial team. Your responsibilities will include defining the product vision and roadmap for commercial data products, ensuring integration and governance of critical data, and collaborating with various stakeholders to support launch readiness. You will also troubleshoot data issues, oversee data integration, and ensure compliance with healthcare data standards.
About You
Required:
- Bachelor's degree in business, computer science, information systems, or related field.
- 5+ years in a Product Owner or Technical Product Manager role, with 9+ years in pharma/biotech.
- Proven experience translating commercial business needs into technical data products.
- Deep knowledge of payer formulary/coverage data and hub/patient services data.
- Strong understanding of HIPAA, patient privacy, and compliance requirements.
Preferred:
- Understanding of gross-to-net drivers (rebates, chargebacks, distribution fees).
- Experience managing third-party vendors and data partners.
- Agile/Scrum certification (CSPO, PSPO) or equivalent.
- Comfort operating in a fast-paced, emerging pharma environment.
Benefits
- Competitive cash compensation.
- Robust equity awards.
- Strong benefits package including health coverage.
- Significant learning and development opportunities.
Revolution Medicines
We are Revolutionaries – passionate in our singular pursuit of discovering, developing and delivering innovative, targeted medicines for patients living with cancer. To deliver on our vision, we work relentlessly in pursuit of cutting-edge therapeutic approaches to some of the toughest cancers. Our current focus is on RAS-addicted cancers, which account for 30 percent of all new human cancer diagnoses.
San Francisco Bay Area